Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry

Executive Summary

Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
Advertisement

Related Content

Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
NICE Demands "Less Biased" Cost Data On Pradaxa For AF
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use
J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance

Topics

Advertisement
UsernamePublicRestriction

Register

PS053692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel